|
|||||
|
|
ARE N-of-1 Trials an Economically Viable Option to Improve Access to Selected High Cost Medications? The Australian Experience |
|
| Authors: | Paul A. Scuffham PhD PG Dip BA Michael J. Yelland MB BS PhD FRACGP FAFMM Jane Nikles MBBS Eva Pietrzak PhD David Wilkinson BSc MBChB MSc MD PhD DSc FRACGP FAFPHM MRCP |
| Affiliation: | School of Medicine, Griffith University, Meadowbrook, Qld, Australia;;School of Medicine, The University of Queensland, Herston, Qld, Australia;;School of Population Health, The University of Queensland, Herston, Qld, Australia;;School of Medicine, The University of Queensland, Herston, Qld, Australia |
| Abstract: | |
| Keywords: | celecoxib chronic neuropathic pain cost-effectiveness gabapentin N-of-1 trials osteoarthritis |